This symposium provided an update in various areas within the fields of diabetes and endocrinology. Topics included the effects of diet and exercise on the metabolic syndrome and cardiovascular disease; programmes to decrease the incidence of diabetes; updates in the genetics of phaeochromocytoma, obesity and type 2 diabetes; the use of pegvisomant in acromegaly and incretin-based therapies in type 2 diabetes; and the relative strengths and weaknesses of bisphosphonates and HRT as treatment for post-menopausal osteoporosis.
Get full access to this article
View all access options for this article.
References
1.
Chief Medical Officer. At least five a week: evidence on the impact of physical activity and its relationship to health. London: Department of Health, 2004
2.
OgilvieDFosterCERothnieHInterventions to promote walking: systematic review. BMJ2007; 334:1204–13
3.
NICE. Four commonly used methods to increase physical activity: brief interventions in primary care, exercise referral schemes, pedometers and community-based exercise programmes for walking and cycling. London: National Institute for Health and Clinical Excellence, 2006
HooperLSummerbellCDHigginsJPDietary fat intake and prevention of cardiovascular disease: systematic review. BMJ2001; 31:757–63
6.
CookNRCutlerJAObarzanekELong-term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ2007; 334:885–8
7.
BazzanoAReynoldsKHolderKNEffect of folic acid supplementation on risk of cardiovascular diseases: meta-analysis of randomized controlled trials. JAMA2006; 296:2720–6
8.
HooperLNessADavey SmithG.Antioxidant strategy for cardiovascular disease. Lancet2001; 357:1705–6
9.
TuomilehtoJLindstromJErikssonJGPrevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001; 344:1343–50
10.
Diabetes Prevention Program Research Group. Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care2005; 28:138–44
11.
PanXRLiGWHuYHEffects of diabetes and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care1997; 20:537–44
12.
RamachandranASnehalathaCMarySIndian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-I). Diabetologia2006; 49:289–97
13.
SilventoinenKPankowJLindstromJThe validity of the Finnish Diabetes Risk Score for the prevention of the incidence of coronary heart disease and stroke and total mortality. Eur J Cardiovasc Prev Rehabil2005; 12:451–8
NeumanHPHBauschBMcWhinneySRGermline mutations in non-syndromic pheochromocytoma. N Engl J Med2002; 346:1459–66
16.
FraylingTMTimpsonNJWeedonMNA common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science2007; 316:889–94
17.
Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University and Novartis Institutes for Bio Medical ResearchSaxenaRVoightBFLyssenkoVGenome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science2007; 316:1331–6
18.
SteinthorsdottirVThorleifssonGReynisdottirIA variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet2007; 39:770–5
19.
ScottLJMohlkeKLBonnycastleLL A genome-side association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science2007; 316:1341–5
20.
SladekRRocheleauGRungJA genome-wide association study identifies novel risk loci for type 2 diabetes. Nature2007; 445:881–5
21.
van der LelyAJHutsonRKTrainerPJLong-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet2001; 358:1754–9
22.
DeFronzoRARatnerREHanJEffects of exenatide (exendin- 4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes. Diabetes Care2005; 28:1092–100
23.
NauckMAMeiningerGShengD Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, noninferiority trial. Diabetes, Obesity and Metabolism2007; 9:194–205
24.
The Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA2002; 288:321–33
25.
MansonJEAllisonMARossouwJEEstrogen therapy and coronary artery calcification. N Engl J Med 2007; 356:2591–602
